This Article Full Text Full Text (PDF) All Versions of this Article: 90/11/6268    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cebrian, A. Articles by Ponder, B. A. J. Search for Related Content PubMed PubMed Citation Articles by Cebrian, A. Articles by Ponder, B. A. J. Related Collections Endocrine Oncology Thyroid

Polymorphisms in the Initiators of RET (Rearranged during Transfection) Signaling Pathway and Susceptibility to Sporadic Medullary Thyroid Carcinoma

Cancer Research UK Human Cancer Genetics Research Group, Department of Oncology, University of Cambridge (A.C., F.L., S.M., J.L., S.A., C.L., P.D.P., A.M.D., B.A.J.P.), Cancer Research UK Genetic Epidemiology Group (P.L.S.), and Department of Public Health and Primary Care (R.L.), Strangeways Research Laboratories, Cambridge CB1 8RN, United Kingdom; Ranier Technology Ltd., Greenhouse Park Innovation Center (S.M.), Cambridge CB1 5AS, United Kingdom; and East Anglican Medical Genetics Service Molecular Genetics Laboratory, Addenbrooke’s Hospital (J.W.), Cambridge CB2 2FF, United Kingdom

Address all correspondence and requests for reprints to: Dr. Arancha Cebrian, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom. E-mail: arancha{at}srl.cam.ac.uk.

Context: Medullary thyroid carcinoma (MTC) is a characteristic tumor occurring in individuals with multiple endocrine neoplasia type 2 who carry germ-line mutations in RET (rearranged during transfection). However, most MTC occur in individuals without a family history.

Objectives: The objective of this study was to explore the possibility that susceptibility in these cases results from low penetrance alleles of RET, its coreceptors, and ligands.

Design: We carried out an association study in 135 sporadic MTC (sMTC) patients and 533 controls from the United Kingdom population.

Results and Conclusions: We analyzed 33 polymorphisms in all nine genes involved in the glial cell line-derived neurotropic factor receptor- (GFR)-RET complex. This is the first association study in which all genes involved in this complex have been investigated for susceptibility to sMTC. We did not find any association between single nucleotide polymorphisms in the exonic regions of the GFR2, GFR3, GFR4, glial cell line-derived neurotropic factor, neurturin, or persephin genes and risk of developing sMTC. We found a strong association between the disease and specific haplotypes of RET. We not only confirmed the previously described association with G691S and S904S (for heterozygotes: odds ratio, 1.85; range, 1.22–2.82; P = 0.004), but we found a novel protective effect associated with a specific haplotype (odds ratio, 0.39; range, 0.21–0.72; P = 0.005) revealing the existence of different genetic variants in the RET oncogene that either increase or decrease risk of sMTC.

This article has been cited by other articles:

				Y. Ito, T. Koessler, A. E.K. Ibrahim, S. Rai, S. L. Vowler, S. Abu-Amero, A.-L. Silva, A.-T. Maia, J. E. Huddleston, S. Uribe-Lewis, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer Hum. Mol. Genet., September 1, 2008; 17(17): 2633 - 2643. [Abstract] [Full Text] [PDF]

				L Foppiani, F Forzano, I Ceccherini, W Bruno, P Ghiorzo, F Caroli, P Quilici, R Bandelloni, A Arlandini, G Sartini, et al. Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene Eur. J. Endocrinol., March 1, 2008; 158(3): 417 - 422. [Abstract] [Full Text] [PDF]

				S. Ruiz-Llorente, C. Montero-Conde, R. L. Milne, C. M. Moya, A. Cebrian, R. Leton, A. Cascon, F. Mercadillo, I. Landa, S. Borrego, et al. Association Study of 69 Genes in the Ret Pathway Identifies Low-penetrance Loci in Sporadic Medullary Thyroid Carcinoma Cancer Res., October 1, 2007; 67(19): 9561 - 9567. [Abstract] [Full Text] [PDF]

				S. Lonn, P. Bhatti, B. H. Alexander, M. A. Pineda, M. M. Doody, J. P. Struewing, and A. J. Sigurdson Papillary Thyroid Cancer and Polymorphic Variants in TSHR- and RET-Related Genes: a Nested Case-Control Study within a Cohort of U.S. Radiologic Technologists Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 174 - 177. [Abstract] [Full Text] [PDF]

				J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]

				F. Lesueur, A. Cebrian, M. Robledo, P. Niccoli-Sire, K.-A. Svensson, S. Pinson, J. Leyland, J. Whittaker, P. D. Pharoah, and B. A.J. Ponder Polymorphisms in RET and Its Coreceptors and Ligands as Genetic Modifiers of Multiple Endocrine Neoplasia Type 2A Cancer Res., January 15, 2006; 66(2): 1177 - 1180. [Abstract] [Full Text] [PDF]